信立泰(002294.SZ):擬以自籌資金約2.5億元向生物醫療增資
格隆匯3月29日丨信立泰(002294.SZ)公佈,根據子公司深圳市信立泰生物醫療工程有限公司(“生物醫療”)融資發展規劃,公司擬以自籌資金人民幣24983.8717萬元,向深圳市信立泰生物醫療工程有限公司增資。增資完成後,生物醫療的註冊資本將由75035.2981萬元增至100019.1698萬元;生物醫療仍為公司全資子公司。
公吿顯示,生物醫療主要從事高端介入醫療器械的研發、生產和銷售,佈局涵蓋心腦血管、外周血管等細分市場領域,目前已建立了完備的球囊擴張導管研發和產業化基地,研發產品包括冠脈與外周球囊擴張導管,以及通過技術引進方式獲取的雷帕黴素藥物洗脱冠脈球囊導管、雷帕黴素藥物洗脱外周球囊導管、微針輸送系統等。其中,雷帕黴素藥物洗脱冠脈球囊導管和雷帕黴素藥物洗脱外周球囊導管正在開展註冊臨牀試驗。同時,生物醫療還將繼續在擴大藥物洗脱球囊產品適應症方面開展研究工作,進一步豐富公司在心腦血管介入治療領域的產品管線,與現有產品形成協同效應,逐步提升公司在心腦血管領域綜合解決方案的地位,是公司主營業務領域的擴展,未來新的業績增長點。
目前,公司正以生物醫療為主體,籌劃醫療器械板塊子公司分拆上市的相關準備工作。
經2020年12月11日第五屆董事會第八次會議審議通過,公司正以生物醫療為上市主體,啟動醫療器械版塊分拆上市的前期籌備工作。此次以自籌資金增資生物醫療,將主要用於清理其與母公司深圳信立泰藥業股份有限公司之間的借款,釐清債權債務關係,以引入新的戰略投資者,進一步加快業務版塊的整合速度。該事項符合子公司業務發展的實際需要,符合公司發展戰略和長遠規劃,不存在損害公司及全體股東,特別是中小股東合法權益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.